에 대한 최신 뉴스 Danaher (NYSE:DHR) 주식

Danaher

In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.

Social Media

Exclusives

Tech

Trading Ideas

LAES

MRVL

SNAP

매주, 벤징가의 스톡 위스퍼 지수(Benzinga&#39;s Stock Whisper Index)는 독점 데이터(proprietary data)와 패턴 인식의 조합을 사용하여 표면 바로 아래에서 주목을 받을 만한 주식 5종목을 소개한다. 투자자들은 가치가 저평가된, 관심이 적은, 새로운 주식들을 항상 찾고 있다. 소매 거래자들이 사용할 수 있는 방법은 무수히 많기 때문에 새로운 기회를 발견하고 특정 주식이 관심을 가져야 하는 이유를 이해하기 위해 풍부한 정보를 조사하는 것이 어려운 경우가 많다.

벤징가의 &#39;스톡 위스퍼&#39; 지수: 스냅, 실스Q, 버티브, 다나허 및 마벨 테크놀로지

Analyst Color

Earnings

Equities

News

Guidance

Health Care

Price Target

Reiteration

Analyst Ratings

General

화요일에, 다나허(NYSE:DHR)는 3분기 매출이 57억 9천만 달러로 전년 대비 3% 증가했으며, 컨센서스 55억 9천만 달러를 상회했다고 보고했다. 가이던스: 다나허(Danaher)는 2024 회계연도 비GAAP 핵심 매출이 전년 대비 낮은 한 자릿수로 감소할 것임을 재확인했다.

다나허의 3분기 실적은 바이오프로세싱 주문 증가로 인해 증가, 분석가는 주식 등급 유지

Movers

AVTR

CBRE

ENPH

FCNCA

LPLA

MANH

SIRI

SPOT

이들 11개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? QXO(NASDAQ:QXO)의 주가는 사모 금융 유치를 발표한 이후 33.37% 상승했다.

유니버셜 헬스 및 록히드 마틴은 지난주 최고 성과를 보여준 11개 대형주 중 일부 (7월 21일-7월 27일)

Danaher Corp

DEUTSCHE EUROSHOP UNS/ADR by Deutsche Euroshop AG

Deutsche EuroShop AG

Each week,&nbsp;Benzinga's Stock Whisper Index&nbsp;uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the&nbsp;<a href="https://www.benzinga.com/topic/stock-whisper-index" target="_blank" rel="noreferrer noopener">surface and deserve attention</a>.
Investors are constantly on the hunt for undervalued, under-followed and emerging stocks. With countless methods available to retail traders, the challenge often lies in sifting through the abundance of information to uncover new opportunities and understand why certain stocks should be of interest.
Read Also:&nbsp;<a href="https://www.benzinga.com/top-stories/24/11/41718416/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-october-2024-where-do-tesla-nvidia-apple-d" target="_blank" rel="noreferrer noopener">EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In October 2024 — Where Do Tesla, Nvidia, Apple, DJT Stock Rank?</a>
Here&#8217;s a look at the Benzinga Stock Whisper Index for the week ending Dec. 13:
Snap Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>): The social media and messaging company saw strong interest from Benzinga readers during the week, which is likely related to the <a href="https://www.benzinga.com/24/12/42369266/meta-reddit-stocks-climb-record-highs-as-tiktoks-battle-against-us-ban-continues-after-court-ruling">continued fight to ban</a> TikTok in the U.S. 
Snap and TikTok social media rivals such as Facebook, Instagram and Reddit could benefit if the app is banned. TikTok lost a fight with the U.S. appeals court recently with parent company ByteDance facing a deadline of Jan. 19, 2025, to sell the U.S. arm to a non-Chinese owner or face app stores removing the platform in America. 
While this could be good news for Snap, the ban is far from over with ByteDance continuing to fight and also concerns that President-elect Donald Trump could halt the ban when he takes over the White House. Snap and other social media platforms are also being targeted <a href="https://www.benzinga.com/24/11/42237670/meta-tiktok-snapchat-could-face-32m-fines-as-australia-enforces-social-media-ban-for-under-16s-while-exempting-youtube">in several countries </a>and states over age restrictions on usage of the platforms, which could push the stock down further.
Snap stock was down on the week, as shown on the Benzinga Pro chart below. The stock is down 30% year-to-date in 2024.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="995" height="499" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13134037/Screenshot-268.png" alt="" class="wp-image-692032" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13134037/Screenshot-268.png 995w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13134037/Screenshot-268-300x150.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13134037/Screenshot-268-768x385.png 768w" sizes="(max-width: 995px) 100vw, 995px" /></a></figure>
SEALSQ Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAES#NASDAQ">LAES</a>): The microchip company saw shares surge on several news items related to drones. The company <a href="https://www.benzinga.com/trading-ideas/movers/24/12/42447155/sealsq-corp-shares-are-up-by-more-than-90-what-you-need-to-know">announced partnerships </a>with leading drone manufacturers Parrot and AgEagle. 
The company plans to launch its new Quantum-Resistant Secure Chips portfolio in 2025, which could keep the stock on the radar of Benzinga readers. Testing for these chips is underway. SEALSQ also<a href="https://www.benzinga.com/24/12/42466578/whats-going-on-with-sealsq-corp-today"> announced a partnership</a> with IC'ALPS to accelerate the development of secure Application Specific Integrated Circuits.
"By combining agility with innovation, we are setting a benchmark for excellence in the competitive global semiconductor industry," SEALSQ CTO Jean Pierre Enguent said.
The drone market has been hot with investors looking for the company's that could benefit from the increase in commercial and military drone applications. Shares of the company surged over 200% on the week.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="999" height="504" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13134056/Screenshot-269.png" alt="" class="wp-image-692033" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13134056/Screenshot-269.png 999w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13134056/Screenshot-269-300x151.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13134056/Screenshot-269-768x387.png 768w" sizes="(max-width: 999px) 100vw, 999px" /></a></figure>
Vertiv Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRT#NYSE">VRT</a>): The critical power and infrastructure company saw strong interest from readers during the week. 
Bank of America analyst Andrew Obin <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/42072226/vertivs-earnings-estimates-raised-by-analyst-amid-improved-margin-outlook">recently reiterated a Buy</a> rating with a price target of $150 on the stock. The analyst said the company revised its organic revenue growth forecast to 12%-14% CAGR for 2024 to 2029, up from prior guidance of 8%-11%. Other analysts have<a href="https://www.benzinga.com/quote/VRT/analyst-ratings"> added their takes</a> on the company recently with Barclays initiating shares with an Equal-Weight rating and $142 price target and Citigroup maintaining a Buy rating and raising the price target from $141 to $155.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="993" height="506" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13134111/Screenshot-270.png" alt="" class="wp-image-692034" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13134111/Screenshot-270.png 993w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13134111/Screenshot-270-300x153.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13134111/Screenshot-270-768x391.png 768w" sizes="(max-width: 993px) 100vw, 993px" /></a></figure>
Danaher Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>): The scientific instrument manufacturing company saw increased interest from readers during the week. 
The stock, which previously was featured on the Stock Whisper Index<a href="https://www.benzinga.com/top-stories/24/06/39551432/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet"> in June</a>, saw an analyst upgrade send shares higher on the week. Bank of America upgraded shares from Neutral to Buy with a price target of $290. The analyst said strategic partnerships and pricing could help drive future growth. 
Danaher reported third-quarter financial results in October with earnings per share and revenue each beating Street forecasts. The company has beaten analyst estimates in more than 10 straight quarters for both revenue and earnings per share. Fourth-quarter earnings are estimated to be in January, which could be a future catalyst for the stock.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="995" height="508" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13134125/Screenshot-271.png" alt="" class="wp-image-692035" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13134125/Screenshot-271.png 995w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13134125/Screenshot-271-300x153.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13134125/Screenshot-271-768x392.png 768w" sizes="(max-width: 995px) 100vw, 995px" /></a></figure>
Marvell Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>): The semiconductor stock is trading higher on the week, which comes with peers reporting results and less than two weeks after the company<a href="https://www.benzinga.com/news/earnings/24/12/42302752/marvell-technology-stock-climbs-after-better-than-expected-q3-results-strong-q4-guidance"> reported third-quarter</a> financial results on Dec. 3. The company beat analyst estimates for both revenue and earnings per share. 
Marvell CEO Matt Murphy highlighted the company's forecast for the fourth quarter, which is driven by custom AI silicon programs that are in volume production. The company recently <a href="https://www.benzinga.com/news/contracts/24/12/42432652/marvell-debuts-game-changing-lpo-chipset-for-data-centers-details">announced the availability </a>for new chips in its interconnect portfolio, which comes as AI-driven data centers could boost the need for optimizing interconnect solutions. 
Several analysts <a href="https://www.benzinga.com/news/earnings/earnings-beats/24/12/42321281/marvell-technology-posts-solid-q3-beat-analysts-raise-forecasts-expect-40-50-earnings-growth">raised their price targets</a> on the stock after the company's third-quarter financial results. Shares are up over 100% year-to-date in 2024.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="999" height="505" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13134140/Screenshot-272.png" alt="" class="wp-image-692036" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13134140/Screenshot-272.png 999w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13134140/Screenshot-272-300x152.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13134140/Screenshot-272-768x388.png 768w" sizes="(max-width: 999px) 100vw, 999px" /></a></figure>
Stay tuned for next week's report, and follow Benzinga Pro for all the latest headlines and&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121324&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">top market-moving stories here.</a>
Read the latest Stock Whisper Index reports here:
<ul>
<li><a href="https://www.benzinga.com/general/space/24/11/42013739/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet-43" target="_blank" rel="noreferrer noopener">November 15</a></li>
<li><a href="https://www.benzinga.com/trading-ideas/24/11/42144099/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet-44" target="_blank" rel="noreferrer noopener">November 22</a></li>
<li><a href="https://www.benzinga.com/real-estate/reit/24/11/42250431/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet-45" target="_blank" rel="noreferrer noopener">November 29</a></li>
<li><a href="https://www.benzinga.com/general/biotech/24/12/42366750/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet">December 6</a></li>
</ul>
Read Next: 
<ul>
<li><a href="http://=https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42353047/exclusive-volt-etf-taps-7-trillion-electrification-boom-fueled-by-ai-power-demand">EXCLUSIVE: VOLT ETF Taps $7 Trillion Electrification Boom Fueled By AI Power Demand</a></li>
</ul>

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet

BofA Securities reports that the Life Sciences Tools sector struggled in fiscal year 2024.
Spending by pharmaceutical and biotech companies dropped after pandemic-related overspending, and demand in China stayed weak. This led some Life Sciences companies to lower their already-conservative fiscal year revenue forecasts as the year progressed.
For most of fiscal year 2024, Life Sciences company valuations remained higher than pre-COVID levels but declined after the U.S. elections.
Looking ahead to fiscal year 2025, initial forecasts and management comments suggest a mixed outlook.
The first half of the year is expected to mirror the challenges of late fiscal year 2024, while the second half could see improvement due to easier year-over-year comparisons, potential economic stimulus in China, and a broader market recovery.
After being cautious for most of the past year, the analyst sees some positive signs. The bioprocess market, important for certain Core Tools vendors, has been improving steadily and is expected to stabilize in 2025.
Although China&#8217;s stimulus has taken longer than expected, it is starting to lead to some new orders.
Valuations are still higher than the historical average, but they aren&#8217;t as high as in previous years, creating some good opportunities for stock picking.
BofA upgraded Danaher Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) to Buy from Neutral, maintaining the <a target="_blank" href="https://www.benzinga.com/quote/DHR/analyst-ratings" rel="noreferrer noopener">price target of $290</a>.
In 2024, Danaher struggled with challenges like reduced bioprocessing inventory, a slowdown in China, and lower spending from biotech and pharma customers.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41465140/danahers-q3-earnings-boosted-by-bioprocessing-order-growth-analyst-maintain-stock-r" rel="noreferrer noopener">Danaher&#8217;s Q3 Earnings Boosted By Bioprocessing Order Growth, Analyst Maintain Stock Rating</a>
Analysts believe that bioprocessing, an important market, is nearly back to normal and should see steady demand in 2025.
Although China is still facing difficulties, BofA expects a strong increase in orders in the fourth quarter due to stimulus efforts, with positive effects likely starting in 2025.
BofA has also upgraded Revvity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RVTY#NYSE">RVTY</a>) from Neutral to Buy with a <a target="_blank" href="https://www.benzinga.com/quote/RVTY/analyst-ratings" rel="noreferrer noopener">price target of $138</a>.
The company is at a turning point after making significant business changes in recent years. While management did not provide guidance for fiscal year 2025 at the recent Analyst Day, the long-term strategy remains largely the same.
Even though the market is stabilizing in FY25, Revvity&#8217;s growth is expected to be below its 6-8% target range. As short-term industry challenges continue to lessen, BofA expects Revvity to perform well, bolstered by recent acquisitions.
Price Action: At last check Friday, DHR stock was down 0.15% at $234.14, and RVTY stock was down 1.56% at $114.21.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/12/42488323/drug-price-hikes-unsupported-by-evidence-cost-us-815-million-icer-report" target="_blank" rel="noreferrer noopener">Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report</a></li>
</ul>

Large Cap

Upgrades

RVTY

Despite Higher Valuations, Some Life Sciences Tools Stocks Create Good Opportunities: Analyst

B of A Securities analyst Derik De Bruin upgrades Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) from Neutral to Buy and maintains the price target from $290 to $290.

B of A Securities Upgrades Danaher to Buy, Maintains Price Target to $290

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/13/24</td>
<td>$270.00</td>
<td>$126.0K</td>
<td>711</td>
<td>1.0K</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$160.00</td>
<td>$162.3K</td>
<td>2.0K</td>
<td>939</td>
</tr>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$310.00</td>
<td>$54.2K</td>
<td>71</td>
<td>742</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$830.00</td>
<td>$28.3K</td>
<td>2.0K</td>
<td>520</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/27/24</td>
<td>$600.00</td>
<td>$96.7K</td>
<td>17</td>
<td>474</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/06/24</td>
<td>$240.00</td>
<td>$279.3K</td>
<td>1.0K</td>
<td>306</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$25.00</td>
<td>$89.1K</td>
<td>8.4K</td>
<td>289</td>
</tr>
<tr>
<td>MEDP</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$340.00</td>
<td>$25.8K</td>
<td>224</td>
<td>178</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/15/27</td>
<td>$25.00</td>
<td>$29.4K</td>
<td>4.1K</td>
<td>145</td>
</tr>
<tr>
<td>ELV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$390.00</td>
<td>$28.2K</td>
<td>348</td>
<td>58</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• For AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we notice a put option sweep that happens to be bearish, expiring in 8 day(s) on December 13, 2024. This event was a transfer of 618 contract(s) at a $270.00 strike. This particular put needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $126.0K, with a price of $205.0 per contract. There were 711 open contracts at this strike prior to today, and today 1006 contract(s) were bought and sold. 
• For JNJ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), we notice a call option trade that happens to be bearish, expiring in 106 day(s) on March 21, 2025. This event was a transfer of 800 contract(s) at a $160.00 strike. The total cost received by the writing party (or parties) was $162.3K, with a price of $203.0 per contract. There were 2021 open contracts at this strike prior to today, and today 939 contract(s) were bought and sold. 
• Regarding HUM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), we observe a call option sweep with bullish sentiment. It expires in 197 day(s) on June 20, 2025. Parties traded 21 contract(s) at a $310.00 strike. This particular call needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $54.2K, with a price of $2582.0 per contract. There were 71 open contracts at this strike prior to today, and today 742 contract(s) were bought and sold. 
• For LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we notice a call option sweep that happens to be neutral, expiring in 15 day(s) on December 20, 2024. This event was a transfer of 13 contract(s) at a $830.00 strike. This particular call needed to be split into 8 different trades to become filled. The total cost received by the writing party (or parties) was $28.3K, with a price of $2176.0 per contract. There were 2007 open contracts at this strike prior to today, and today 520 contract(s) were bought and sold. 
• Regarding UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we observe a call option sweep with bullish sentiment. It expires in 22 day(s) on December 27, 2024. Parties traded 117 contract(s) at a $600.00 strike. This particular call needed to be split into 17 different trades to become filled. The total cost received by the writing party (or parties) was $96.7K, with a price of $830.0 per contract. There were 17 open contracts at this strike prior to today, and today 474 contract(s) were bought and sold. 
• Regarding DHR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>), we observe a put option sweep with bearish sentiment. It expires in 1 day(s) on December 6, 2024. Parties traded 266 contract(s) at a $240.00 strike. This particular put needed to be split into 16 different trades to become filled. The total cost received by the writing party (or parties) was $279.3K, with a price of $1050.0 per contract. There were 1000 open contracts at this strike prior to today, and today 306 contract(s) were bought and sold. 
• For HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we notice a call option trade that happens to be neutral, expiring in 43 day(s) on January 17, 2025. This event was a transfer of 99 contract(s) at a $25.00 strike. The total cost received by the writing party (or parties) was $89.1K, with a price of $900.0 per contract. There were 8479 open contracts at this strike prior to today, and today 289 contract(s) were bought and sold. 
• Regarding MEDP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDP#NASDAQ">MEDP</a>), we observe a put option sweep with bullish sentiment. It expires in 15 day(s) on December 20, 2024. Parties traded 30 contract(s) at a $340.00 strike. This particular put needed to be split into 12 different trades to become filled. The total cost received by the writing party (or parties) was $25.8K, with a price of $860.0 per contract. There were 224 open contracts at this strike prior to today, and today 178 contract(s) were bought and sold. 
• For PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we notice a call option trade that happens to be neutral, expiring in 771 day(s) on January 15, 2027. This event was a transfer of 70 contract(s) at a $25.00 strike. The total cost received by the writing party (or parties) was $29.4K, with a price of $420.0 per contract. There were 4153 open contracts at this strike prior to today, and today 145 contract(s) were bought and sold. 
• For ELV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>), we notice a put option sweep that happens to be bearish, expiring in 15 day(s) on December 20, 2024. This event was a transfer of 47 contract(s) at a $390.00 strike. This particular put needed to be split into 18 different trades to become filled. The total cost received by the writing party (or parties) was $28.2K, with a price of $600.0 per contract. There were 348 open contracts at this strike prior to today, and today 58 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

AMGN

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

Hims & Hers Health, Inc. Class A Common Stock

HIMS

MEDP

10 Health Care Stocks Whale Activity In Today's Session

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MDT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/06/24</td>
<td>$86.00</td>
<td>$29.5K</td>
<td>72</td>
<td align="right">680</td>
</tr>
<tr>
<td>GEHC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/06/24</td>
<td>$84.00</td>
<td>$41.1K</td>
<td>24</td>
<td align="right">368</td>
</tr>
<tr>
<td>IBRX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>05/16/25</td>
<td>$4.50</td>
<td>$25.0K</td>
<td>635</td>
<td align="right">330</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$720.00</td>
<td>$227.0K</td>
<td>99</td>
<td align="right">293</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/29/24</td>
<td>$26.00</td>
<td>$94.8K</td>
<td>2.4K</td>
<td align="right">168</td>
</tr>
<tr>
<td>BSX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$75.00</td>
<td>$259.5K</td>
<td>533</td>
<td align="right">150</td>
</tr>
<tr>
<td>APLT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$5.00</td>
<td>$33.0K</td>
<td>6.4K</td>
<td align="right">135</td>
</tr>
<tr>
<td>HROW</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$50.00</td>
<td>$31.9K</td>
<td>776</td>
<td align="right">118</td>
</tr>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$240.00</td>
<td>$55.0K</td>
<td>491</td>
<td align="right">114</td>
</tr>
<tr>
<td>PSTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$5.00</td>
<td>$44.2K</td>
<td>85</td>
<td align="right">110</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding MDT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), we observe a put option sweep with bearish sentiment. It expires in 7 day(s) on December 6, 2024. Parties traded 674 contract(s) at a $86.00 strike. This particular put needed to be split into 44 different trades to become filled. The total cost received by the writing party (or parties) was $29.5K, with a price of $44.0 per contract. There were 72 open contracts at this strike prior to today, and today 680 contract(s) were bought and sold. 
• Regarding GEHC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEHC#NASDAQ">GEHC</a>), we observe a put option sweep with neutral sentiment. It expires in 7 day(s) on December 6, 2024. Parties traded 360 contract(s) at a $84.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $41.1K, with a price of $113.0 per contract. There were 24 open contracts at this strike prior to today, and today 368 contract(s) were bought and sold. 
• Regarding IBRX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>), we observe a put option sweep with neutral sentiment. It expires in 168 day(s) on May 16, 2025. Parties traded 260 contract(s) at a $4.50 strike. This particular put needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $25.0K, with a price of $95.0 per contract. There were 635 open contracts at this strike prior to today, and today 330 contract(s) were bought and sold. 
• Regarding LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we observe a put option trade with bullish sentiment. It expires in 112 day(s) on March 21, 2025. Parties traded 100 contract(s) at a $720.00 strike. The total cost received by the writing party (or parties) was $227.0K, with a price of $2270.0 per contract. There were 99 open contracts at this strike prior to today, and today 293 contract(s) were bought and sold. 
• For HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we notice a call option sweep that happens to be bearish, is expiring today. Parties traded 158 contract(s) at a $26.00 strike. This particular call needed to be split into 8 different trades to become filled. The total cost received by the writing party (or parties) was $94.8K, with a price of $600.0 per contract. There were 2480 open contracts at this strike prior to today, and today 168 contract(s) were bought and sold. 
• Regarding BSX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>), we observe a call option sweep with bullish sentiment. It expires in 84 day(s) on February 21, 2025. Parties traded 150 contract(s) at a $75.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $259.5K, with a price of $1730.0 per contract. There were 533 open contracts at this strike prior to today, and today 150 contract(s) were bought and sold. 
• Regarding APLT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLT#NASDAQ">APLT</a>), we observe a put option trade with bearish sentiment. It expires in 49 day(s) on January 17, 2025. Parties traded 110 contract(s) at a $5.00 strike. The total cost received by the writing party (or parties) was $33.0K, with a price of $300.0 per contract. There were 6422 open contracts at this strike prior to today, and today 135 contract(s) were bought and sold. 
• For HROW (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HROW#NASDAQ">HROW</a>), we notice a put option sweep that happens to be bullish, expiring in 413 day(s) on January 16, 2026. This event was a transfer of 19 contract(s) at a $50.00 strike. This particular put needed to be split into 11 different trades to become filled. The total cost received by the writing party (or parties) was $31.9K, with a price of $1680.0 per contract. There were 776 open contracts at this strike prior to today, and today 118 contract(s) were bought and sold. 
• For DHR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>), we notice a call option trade that happens to be bearish, expiring in 21 day(s) on December 20, 2024. This event was a transfer of 110 contract(s) at a $240.00 strike. The total cost received by the writing party (or parties) was $55.0K, with a price of $500.0 per contract. There were 491 open contracts at this strike prior to today, and today 114 contract(s) were bought and sold. 
• For PSTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTX#NASDAQ">PSTX</a>), we notice a call option trade that happens to be bullish, expiring in 49 day(s) on January 17, 2025. This event was a transfer of 100 contract(s) at a $5.00 strike. The total cost received by the writing party (or parties) was $44.2K, with a price of $442.0 per contract. There were 85 open contracts at this strike prior to today, and today 110 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

APLT

GEHC

HROW

IBRX

PSTX

10 Health Care Stocks With Whale Alerts In Today's Session

Investors with a lot of money to spend have taken a bullish stance on Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether this is an institution or just a wealthy individual, we don't know. But when something this big happens with DHR, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 8 options trades for Danaher.
This isn't normal.
The overall sentiment of these big-money traders is split between 37% bullish and 37%, bearish.
Out of all of the options we uncovered, 7 are puts, for a total amount of $747,642, and there was 1 call, for a total amount of $104,610.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $235.0 to $260.0 for Danaher over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Danaher's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Danaher's significant trades, within a strike price range of $235.0 to $260.0, over the past month.
<h3>Danaher 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732129237_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$28.9</td>
<td>$28.4</td>
<td>$28.43</td>
<td>$260.00</td>
<td>$182.8K</td>
<td>1.6K</td>
<td align="right">136</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$29.7</td>
<td>$28.3</td>
<td>$28.41</td>
<td>$260.00</td>
<td>$154.1K</td>
<td>1.6K</td>
<td align="right">72</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$19.8</td>
<td>$19.5</td>
<td>$19.5</td>
<td>$250.00</td>
<td>$152.8K</td>
<td>1.9K</td>
<td align="right">80</td>
</tr>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/29/24</td>
<td>$2.1</td>
<td>$1.9</td>
<td>$1.9</td>
<td>$235.00</td>
<td>$104.6K</td>
<td>557</td>
<td align="right">551</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$28.9</td>
<td>$28.5</td>
<td>$28.5</td>
<td>$260.00</td>
<td>$91.5K</td>
<td>1.6K</td>
<td align="right">212</td>
</tr>
</tbody>
</table>

<h3>About Danaher</h3>
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divesititure of its environmental and applied solutions group, Veralto.
<h3>Where Is Danaher Standing Right Now?</h3>
<ul>
<li>With a volume of 1,313,444, the price of DHR is up 0.34% at $231.63. </li>
<li>RSI indicators hint that the underlying stock may be oversold.</li>
<li>Next earnings are expected to be released in 69 days.</li>
</ul>
<h3>Expert Opinions on Danaher</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $305.2.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from RBC Capital persists with their Outperform rating on Danaher, maintaining a target price of $311. 
&#x2A; Reflecting concerns, an analyst from Stephens &amp; Co. lowers its rating to Overweight with a new price target of $315. 
&#x2A; An analyst from UBS persists with their Buy rating on Danaher, maintaining a target price of $305. 
&#x2A; An analyst from Wolfe Research upgraded its action to Outperform with a price target of $285. 
&#x2A; Consistent in their evaluation, an analyst from Keybanc keeps a Overweight rating on Danaher with a target price of $310. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Danaher with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Markets

What the Options Market Tells Us About Danaher

Investors with a lot of money to spend have taken a bearish stance on Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with DHR, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 11 uncommon options trades for Danaher.
This isn't normal.
The overall sentiment of these big-money traders is split between 18% bullish and 81%, bearish.
Out of all of the special options we uncovered, 9 are puts, for a total amount of $574,327, and 2 are calls, for a total amount of $150,000.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $210.0 to $260.0 for Danaher over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
In today's trading context, the average open interest for options of Danaher stands at 431.56, with a total volume reaching 1,664.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Danaher, situated within the strike price corridor from $210.0 to $260.0, throughout the last 30 days.
<h3>Danaher 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731701829_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$11.5</td>
<td>$11.0</td>
<td>$11.2</td>
<td>$230.00</td>
<td>$163.5K</td>
<td>1.3K</td>
<td align="right">139</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$4.9</td>
<td>$4.3</td>
<td>$4.9</td>
<td>$230.00</td>
<td>$147.0K</td>
<td>1.1K</td>
<td align="right">300</td>
</tr>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$44.8</td>
<td>$42.7</td>
<td>$44.1</td>
<td>$230.00</td>
<td>$110.2K</td>
<td>0</td>
<td align="right">25</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$0.95</td>
<td>$0.9</td>
<td>$0.9</td>
<td>$210.00</td>
<td>$62.8K</td>
<td>126</td>
<td align="right">699</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$31.6</td>
<td>$30.2</td>
<td>$30.7</td>
<td>$260.00</td>
<td>$61.4K</td>
<td>205</td>
<td align="right">30</td>
</tr>
</tbody>
</table>

<h3>About Danaher</h3>
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divesititure of its environmental and applied solutions group, Veralto.
After a thorough review of the options trading surrounding Danaher, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Present Market Standing of Danaher</h3>
<ul>
<li>With a trading volume of 3,258,575, the price of DHR is down by -1.73%, reaching $235.23.</li>
<li>Current RSI values indicate that the stock is may be oversold.</li>
<li>Next earnings report is scheduled for 74 days from now.</li>
</ul>
<h3>Expert Opinions on Danaher</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $288.4.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from TD Cowen has decided to maintain their Buy rating on Danaher, which currently sits at a price target of $315. 
&#x2A; An analyst from Barclays persists with their Equal-Weight rating on Danaher, maintaining a target price of $275. 
&#x2A; An analyst from Baird persists with their Outperform rating on Danaher, maintaining a target price of $277. 
&#x2A; An analyst from Stifel persists with their Hold rating on Danaher, maintaining a target price of $265. 
&#x2A; Maintaining their stance, an analyst from Keybanc continues to hold a Overweight rating for Danaher, targeting a price of $310. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Danaher, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

WIIM

Danaher shares are trading lower after Third Point in a 13F disclosed that it decreased its stake in the company by 5%

AAPL

AMZN

MSFT

Third Point 13F Shows Decreased Stake In PG&E Corp By 7% From 53,750,000 To 49,750,000 Shares; Amazon By 27% From 5,100,000 To 3,700,000 Shares; Danaher Corp By 5% From 2,050,000 To 1,950,000 Shares; Vistra Corp By 29% From 4,470,000 To 3,175,000 Shares; Microsoft By 45% From 1,580,000 To 870,000 Shares; Meta Platforms By 50% From 1,100,000  To 545,000 Shares; TSM By 12% From 2,025,000 To 1,780,000 Shares; Apple By 52% From 1,950,000 To 930,000 Shares; Amphenol Corp By 43% From 2,800,000 To 1,600,000 Shares

Danaher's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) short percent of float has fallen 5.68% since its last report. The company recently reported that it has 5.32 million shares sold short, which is 0.83% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.63 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Danaher Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730733432_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Danaher has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Danaher's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Danaher's peer group average for short interest as a percentage of float is 5.39%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into Danaher's Recent Short Interest

In the fast-paced and highly competitive business world of today, conducting thorough company analysis is essential for investors and industry observers. In this article, we will conduct an extensive industry comparison, evaluating Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) in relation to its major competitors in the Life Sciences Tools &amp; Services industry. Through a detailed examination of key financial metrics, market standing, and growth prospects, our objective is to provide valuable insights and illuminate company's performance in the industry.
<h3>Danaher Background</h3>
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divesititure of its environmental and applied solutions group, Veralto.
<table>
<thead>
<tr>
<th>Company</th>
<th>P/E</th>
<th>P/B</th>
<th>P/S</th>
<th>ROE</th>
<th>EBITDA (in billions)</th>
<th>Gross Profit (in billions)</th>
<th>Revenue Growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Danaher Corp</td>
<td>46.75</td>
<td>3.49</td>
<td>7.74</td>
<td>1.62%</td>
<td>$1.66</td>
<td>$3.4</td>
<td>3.09%</td>
</tr>
<tr>
<td>Thermo Fisher Scientific Inc</td>
<td>34.98</td>
<td>4.36</td>
<td>5.06</td>
<td>3.38%</td>
<td>$2.91</td>
<td>$4.35</td>
<td>0.54%</td>
</tr>
<tr>
<td>Agilent Technologies Inc</td>
<td>28.46</td>
<td>6.66</td>
<td>6.19</td>
<td>4.65%</td>
<td>$0.43</td>
<td>$0.85</td>
<td>-5.62%</td>
</tr>
<tr>
<td>IQVIA Holdings Inc</td>
<td>27.48</td>
<td>5.45</td>
<td>2.52</td>
<td>4.17%</td>
<td>$0.8</td>
<td>$1.38</td>
<td>4.28%</td>
</tr>
<tr>
<td>Waters Corp</td>
<td>36.95</td>
<td>14.34</td>
<td>7.92</td>
<td>10.71%</td>
<td>$0.24</td>
<td>$0.42</td>
<td>4.02%</td>
</tr>
<tr>
<td>West Pharmaceutical Services Inc</td>
<td>46.96</td>
<td>8.33</td>
<td>8.15</td>
<td>5.1%</td>
<td>$0.21</td>
<td>$0.26</td>
<td>-0.07%</td>
</tr>
<tr>
<td>Avantor Inc</td>
<td>49.58</td>
<td>2.73</td>
<td>2.23</td>
<td>1.05%</td>
<td>$0.23</td>
<td>$0.56</td>
<td>-0.34%</td>
</tr>
<tr>
<td>Revvity Inc</td>
<td>75.65</td>
<td>1.90</td>
<td>5.52</td>
<td>0.7%</td>
<td>$0.22</td>
<td>$0.39</td>
<td>-2.45%</td>
</tr>
<tr>
<td>Bio-Techne Corp</td>
<td>79.27</td>
<td>5.59</td>
<td>10.32</td>
<td>1.6%</td>
<td>$0.07</td>
<td>$0.2</td>
<td>-5.44%</td>
</tr>
<tr>
<td>Medpace Holdings Inc</td>
<td>27.98</td>
<td>11.27</td>
<td>4.94</td>
<td>11.72%</td>
<td>$0.12</td>
<td>$0.17</td>
<td>8.29%</td>
</tr>
<tr>
<td>Charles River Laboratories International Inc</td>
<td>21.65</td>
<td>2.51</td>
<td>2.29</td>
<td>2.44%</td>
<td>$0.24</td>
<td>$0.35</td>
<td>-3.19%</td>
</tr>
<tr>
<td>Bruker Corp</td>
<td>24.81</td>
<td>5.02</td>
<td>2.79</td>
<td>0.47%</td>
<td>$0.08</td>
<td>$0.38</td>
<td>17.42%</td>
</tr>
<tr>
<td>Stevanato Group SpA</td>
<td>39.22</td>
<td>4.39</td>
<td>4.43</td>
<td>1.55%</td>
<td>$0.05</td>
<td>$0.07</td>
<td>1.67%</td>
</tr>
<tr>
<td>Sotera Health Co</td>
<td>113.29</td>
<td>10.62</td>
<td>4.10</td>
<td>2.05%</td>
<td>$0.1</td>
<td>$0.15</td>
<td>8.35%</td>
</tr>
<tr>
<td>Average</td>
<td>46.64</td>
<td>6.4</td>
<td>5.11</td>
<td>3.81%</td>
<td>$0.44</td>
<td>$0.73</td>
<td>2.11%</td>
</tr>
</tbody>
</table>
<style>
 table {
 width: 100%;
 border-collapse: collapse;
 font-family: Arial, sans-serif;
 font-size: 14px;
 }

 th, td {
 padding: 8px;
 text-align: left;
 }

 th {
 background-color: #293a5a;
 color: #fff;
 text-align: left;
 }

 tr:nth-child(even) {
 background-color: #f2f4f8;
 }

 tr:hover {
 background-color: #e1e4ea;
 }

 td:nth-child(3), td:nth-child(5) {
 text-align: left;
 }

 .dividend-amount {
 font-weight: bold;
 color: #0d6efd;
 }

 .dividend-frequency {
 font-size: 12px;
 color: #6c757d;
 }
 </style>Upon a comprehensive analysis of Danaher, the following trends can be discerned: 
<ul>
<li>
The Price to Earnings ratio of 46.75 for this company is 1.0x above the industry average, indicating a premium valuation associated with the stock.
</li>
<li>
With a Price to Book ratio of 3.49, significantly falling below the industry average by 0.55x, it suggests undervaluation and the possibility of untapped growth prospects.
</li>
<li>
The stock's relatively high Price to Sales ratio of 7.74, surpassing the industry average by 1.51x, may indicate an aspect of overvaluation in terms of sales performance.
</li>
<li>
The company has a lower Return on Equity (ROE) of 1.62%, which is 2.19% below the industry average. This indicates potential inefficiency in utilizing equity to generate profits, which could be attributed to various factors.
</li>
<li>
With higher Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) of $1.66 Billion, which is 3.77x above the industry average, the company demonstrates stronger profitability and robust cash flow generation.
</li>
<li>
Compared to its industry, the company has higher gross profit of $3.4 Billion, which indicates 4.66x above the industry average, indicating stronger profitability and higher earnings from its core operations.
</li>
<li>
The company is experiencing remarkable revenue growth, with a rate of 3.09%, outperforming the industry average of 2.11%.
</li>
</ul>
<h3>Debt To Equity Ratio</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730732622_0.png" alt="debt to equity" />
The debt-to-equity (D/E) ratio indicates the proportion of debt and equity used by a company to finance its assets and operations.
Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health and risk profile, aiding in informed decision-making.
When assessing Danaher against its top 4 peers using the Debt-to-Equity ratio, the following comparisons can be made:
<ul>
<li>
Danaher exhibits a stronger financial position compared to its top 4 peers in the sector, as indicated by its lower debt-to-equity ratio of 0.34.
</li>
<li>
This suggests that the company has a more favorable balance between debt and equity, which can be seen as a positive aspect for investors.
</li>
</ul>
<h3>Key Takeaways</h3>
For Danaher in the Life Sciences Tools &amp; Services industry, the PE ratio is high compared to peers, indicating potential overvaluation. The PB ratio is low, suggesting a possible undervaluation relative to industry standards. The PS ratio is high, signaling a premium valuation based on sales. In terms of ROE, Danaher shows lower profitability compared to peers. However, its high EBITDA, gross profit, and revenue growth reflect strong operational performance within the industry sector.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Inquiry Into Danaher's Competitor Dynamics In Life Sciences Tools &amp; Services Industry

In the current market session, Danaher Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) share price is at $242.91, after a 0.09% spike. Moreover, over the past month, the stock decreased by 8.25%, but in the past year, went up by 26.72%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2024/1730491548_0.png" alt="Past Year Chart" />

<h3>Danaher P/E Compared to Competitors</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Danaher has a better P/E ratio of 45.79 than the aggregate P/E ratio of 43.15 of the Life Sciences Tools &amp; Services industry. Ideally, one might believe that Danaher Inc. might perform better in the future than it's industry group, but it's probable that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1730491548_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

A Look Into Danaher Inc's Price Over Earnings

Wolfe Research analyst Doug Schenkel upgrades Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) from Peer Perform to Outperform and announces $285 price target.

Wolfe Research Upgrades Danaher to Outperform, Announces $285 Price Target

Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) has outperformed the market over the past 10 years by 5.16% on an annualized basis producing an average annual return of 16.37%. Currently, Danaher has a market capitalization of $176.82 billion. 
Buying $1000 In DHR: If an investor had bought $1000 of DHR stock 10 years ago, it would be worth $4,556.76 today based on a price of $244.81 for DHR at the time of writing.
<h3>Danaher's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730129417_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 10 Years Ago, You Would Have $4,600 Today

RBC Capital analyst Conor McNamara maintains Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) with a Outperform and lowers the price target from $333 to $311.

RBC Capital Maintains Outperform on Danaher, Lowers Price Target to $311

TD Cowen analyst Dan Brennan maintains Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) with a Buy and raises the price target from $310 to $315.

TD Cowen Maintains Buy on Danaher, Raises Price Target to $315

Stephens &amp; Co. analyst Jacob Johnson reiterates Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) with a Overweight and maintains $315 price target.

Stephens & Co. Reiterates Overweight on Danaher, Maintains $315 Price Target

Stifel analyst Daniel Arias maintains Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) with a Hold and raises the price target from $250 to $265.

Stifel Maintains Hold on Danaher, Raises Price Target to $265

UBS analyst Dan Leonard maintains Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) with a Buy and lowers the price target from $309 to $305.

UBS Maintains Buy on Danaher, Lowers Price Target to $305

Raymond James analyst Andrew Cooper maintains Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) with a Outperform and lowers the price target from $310 to $300.

Raymond James Maintains Outperform on Danaher, Lowers Price Target to $300

Wells Fargo's 'Core' List: GOOGL, DIS, HD, WMT, and more

Danaher: A Resilient And Solid Company With Growth Potential

Thermo Fisher Scientific: Renewed Growth Momentum After The Pandemic

Danaher declares $0.27 dividend

In a report released on December 8, Conor McNamara from RBC Capital maintained a Buy rating on Danaher (DHR – Research Report), with a price target...

RBC Capital Remains a Buy on Danaher (DHR)

Thermo Fisher: The Cycle Has Already Turned Around

BofA upgraded Danaher (DHR) to Buy from Neutral with an unchanged price target of $290. The recent pullback has created a more attractive entry poi...

Danaher upgraded to Buy at BofA following pullback

BofA upgraded Danaher (DHR) to Buy from Neutral with a $290 price target Published first on TheFly – the ultimate source for real-time, market-movi...

Danaher upgraded to Buy from Neutral at BofA

Analyst Tycho Peterson of Jefferies maintained a Buy rating on Danaher (DHR – Research Report), reducing the price target to $285.00. Tycho Peterso...

Danaher Buy Rating: Strategic Partnerships and Pricing Initiatives Drive Growth Potential

Best Way To Invest $100,000: Build An 8-Stock Portfolio For Growth And Value

ABBV

ADBE

AVGO

BKNG

CMCSA

COST

CSCO

CTVA

GOOG

GOOGL

ISRG

LSTR

MDLZ

NFLX

NVDA

ORCL

PAYX

SBUX

SNPS

TMUS

TSLA

TTWO

UBER

Press Releases

Danaher Announces Two New Centers of Innovation in Diagnostics to Transform Precision Medicine Development

Beckman Coulter's DxI 9000 Immunoassay Analyzer Honored at Premier, Inc.'s Annual Supplier Innovation Celebration

Danaher to Webcast Diagnostics Investor & Analyst Meeting in Washington, D.C.

Danaher Confirms Third Quarter and Full Year 2024 Guidance

Dividends

Danaher Announces Quarterly Dividend

Beckman Coulter and Scopio Labs Add World's First Digital Bone Marrow Imaging and Analysis to Long-Term Partnership

Danaher Schedules Third Quarter 2024 Earnings Conference Call

Danaher Reports Third Quarter 2024 Results

Danaher to Present at Evercore ISI HealthCONx Conference

Agilent Technologies

AbCellera Biologics

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solns

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Evotec

Fortrea Holdings

Illumina

IQVIA Hldgs

Medpace Hldgs

Mettler-Toledo International, Inc. Common Stock

Mettler-Toledo Intl

Repligen

Revvity

Sotera Health

Stevanato Group

Bio-Techne

Tempus AI

Thermo Fisher Scientific Inc Common Stock

Thermo Fisher Scientific

10x Genomics

Waters

West Pharmaceutical Services, Inc. Common Stock

West Pharmaceutical Servs

B of A Securities

Wolfe Research

RBC Capital

TD Cowen

Keybanc

매주, 벤징가의 스톡 위스퍼 지수(Benzinga's Stock Whisper Index)는 독점 데이터(proprietary data)와 패턴 인식의 조합을 사용하여 <a href="https://www.benzinga.com/topic/stock-whisper-index" target="_blank" rel="noreferrer noopener">표면 바로 아래에서 주목</a>을 받을 만한 주식 5종목을 소개한다.
투자자들은 가치가 저평가된, 관심이 적은, 새로운 주식들을 항상 찾고 있다. 소매 거래자들이 사용할 수 있는 방법은 무수히 많기 때문에 새로운 기회를 발견하고 특정 주식이 관심을 가져야 하는 이유를 이해하기 위해 풍부한 정보를 조사하는 것이 어려운 경우가 많다.
다음은 12월 13일로 끝나는 주간의 벤징가 ‘스톡 위스퍼' 지수의 개요:
1. 스냅 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>):
<div class="ticker-wrapper">
<div class="sc-icgYrN gsJcQM ticker-box-wrapper">
<div>
<div class="relative w-fit"></div>
</div>
<div class="sc-hZlppA ddOBfh get-report-button flex">
<div class="flex items-center ml-2 text-sm text-blue-500">소셜 미디어 및 메신저 회사인 스냅은 벤징가 독자들로부터 강한 관심을 받았다. 이는 미국에서 틱톡 <a style="font-size: revert;" href="https://www.benzinga.com/24/12/42369266/meta-reddit-stocks-climb-record-highs-as-tiktoks-battle-against-us-ban-continues-after-court-ruling" target="_blank" rel="noopener">금지 운동이 계속되고 있는 것</a>과 관련이 있을 가능성이 크다.</div>
</div>
</div>
</div>
스냅과 틱톡의 소셜 미디어 경쟁자인 페이스북, 인스타그램 및 레딧 등은 틱톡이 금지될 경우 이점을 누릴 수 있다. 최근 틱톡은 미국 항소 법원과의 싸움에서 패배했으며, 모회사 바이트댄스는 2025년 1월 19일까지 미국 자회사를 비중국인 소유자에게 매각하지 않으면 앱 스토어에서 플랫폼이 제거된다는 기한을 받았다.
이것이 스냅에게는 긍정적인 소식이 될 수 있지만, 금지 조치는 아직 끝나지 않았으며, 바이트댄스가 계속해서 싸울 것이란 우려와 함께 도널드 트럼프 대통령 당선자가 백악관을 인수할 때 금지 조치를 중단할 수 있다는 우려도 있다. 또한 스냅과 다른 소셜 미디어 플랫폼들은 <a href="https://www.benzinga.com/24/11/42237670/meta-tiktok-snapchat-could-face-32m-fines-as-australia-enforces-social-media-ban-for-under-16s-while-exempting-youtube" target="_blank" rel="noopener">여러 국가</a>와 주들에서 사용 연령 제한으로 인해 중단 조치를 받을 수 있다. 주가가 더 하락할 수 있다.
스냅의 주가는 금요일 0.62% 하락한 11.31달러에 마감되었다. 이번 주에는 9.52% 하락했으며, 2024년 연초 대비 주가가 29.93% 하락했다.
<img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13134037/Screenshot-268.png?optimize=medium&amp;dpr=1.25&amp;auto=webp&amp;width=2048" />
2. 실스Q (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAES#NASDAQ">LAES</a>):
마이크로칩 회사인 실스Q(SEALSQ)는 드론과 관련된 여러 뉴스로 인해 주가가 급등했다. 이 회사는 패럿(Parrot)과 에이지이글(AgEagle)과의 <a href="https://www.benzinga.com/trading-ideas/movers/24/12/42447155/sealsq-corp-shares-are-up-by-more-than-90-what-you-need-to-know" target="_blank" rel="noopener">파트너십을 발표</a>했다.
이 회사는 2025년에 새로운 양자 저항 보안 칩 포트폴리오를 출시할 계획이다. 이로 인해 주가가 Benzinga 독자들의 주목을 받을 수 있게 된다. 이러한 칩에 대한 테스트가 진행 중이며, 실스Q는 IC 알프스(IC&#8217;ALPS)와의 <a href="https://www.benzinga.com/24/12/42466578/whats-going-on-with-sealsq-corp-today" target="_blank" rel="noopener">파트너십을 발표</a>하여 보안 애플리케이션 전용 집적 회로의 개발을 가속화했다.
&#8220;우리는 민첩성과 혁신을 결합함으로써 글로벌 반도체 산업에서 우수성의 기준을 설정하고 있다&#8221;고 실스Q의 CTO인 장 피에르 앙구앙(Jean Pierre Enguent)가 말했다.
드론 시장은 상업용 및 군용 드론 애플리케이션의 증가로 인해 투자자들이 주목하고 있는 핫한 시장이다. 실스Q의 주가는 이번 주에 297.82% 급등했다. 금요일 이 주식은 5.41% 하락한 1.75달러에 마감했으나 이후 시간외 거래에서 10.29% 급등했다.
<img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13134056/Screenshot-269.png?optimize=medium&amp;dpr=1.25&amp;auto=webp&amp;width=2048" />
3. 버티브 홀딩스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRT#NYSE">VRT</a>):
필수 전력 및 인프라 회사인 버티브(Vertiv)는 이번 주에 독자들로부터 강한 관심을 받았다.
뱅크 오브 아메리카의 애널리스트인 앤드류 오빈(Andrew Obin)은 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/42072226/vertivs-earnings-estimates-raised-by-analyst-amid-improved-margin-outlook" target="_blank" rel="noopener">최근 주식에 대해 매수 등급을 재확인</a>하고 목표 주가를 150달러로 설정했다. 이 애널리스트는 이 회사가 2024년부터 2029년까지의 유기적 매출 성장 전망을 12%-14%로 상향 조정했다고 밝혔다. 다른 애널리스트들도 최근 버티브에 대한 의견을 추가했으며, 바클레이즈는 주식을 중립 등급으로 시작하고 목표 주가를 142달러로 <a href="https://www.benzinga.com/quote/VRT/analyst-ratings" target="_blank" rel="noopener">설정</a>했으며, 씨티그룹은 매수 등급을 유지하고 목표 주가를 141달러에서 155달러로 상향 조정했다.
<img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13134111/Screenshot-270.png?optimize=medium&amp;dpr=1.25&amp;auto=webp&amp;width=2048" />
4. 다나허 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>):
과학 기기 제조 회사인 다나허(Danaher)는 이번 주에 독자들로부터 증가된 관심을 받았다.
이 주식은 이전에 <a href="https://www.benzinga.com/top-stories/24/06/39551432/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noopener">6월에</a> 주식 속삭임 지수에 등장했으며, 애널리스트의 업그레이드가 주가를 상승시켰다. 뱅크 오브 아메리카는 중립에서 매수로 주식을 상향 조정하고, 목표 주가를 290달러로 설정했다. 이 애널리스트는 전략적 파트너십과 가격 책정이 향후 성장에 기여할 수 있다고 말했다.
다나허는 3분기 재무 결과를 10월에 발표했으며, 주당 순이익과 매출 모두 시장 예상을 초과했다. 이 회사는 매출과 주당 순이익 모두에서 10분기 연속으로 애널리스트 예상을 초과했다. 4분기 실적은 1월에 발표될 예정이며, 이는 주식에 대한 미래 촉매제가 될 수 있다.
<img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13134125/Screenshot-271.png?optimize=medium&amp;dpr=1.25&amp;auto=webp&amp;width=2048" />
5. 마벨 테크놀로지 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>):
반도체 주식인 마벨은 동료들이 실적을 발표하고 회사가 12월 3일에 3분기 <a href="https://kr.benzinga.com/news/usa/stocks/%EB%A7%88%EB%B2%A8-%ED%85%8C%ED%81%AC%EB%86%80%EB%A1%9C%EC%A7%80-3%EB%B6%84%EA%B8%B0-%ED%98%B8%EC%8B%A4%EC%A0%81-%EB%B0%8F-4%EB%B6%84%EA%B8%B0-%EA%B0%95%EB%A0%A5%ED%95%9C-%EC%A0%84%EB%A7%9D-%EB%B0%9C/" target="_blank" rel="noopener">재무 결과를 발표</a>한 지 2주도 채 안 된 시점에서 주가가 상승하고 있다. 이 회사는 매출과 주당 순이익 모두에서 애널리스트의 예상치를 초과했다.
마벨의 CEO 맷 머피(Matt Murphy)는 회사의 4분기 전망이 맞춤형 AI 실리콘 프로그램의 대량 생산에 의해 주도되고 있음을 강조했다. 이 회사는 최근 데이터 센터를 위한 새로운 인터커넥트 포트폴리오 칩의 <a href="https://www.benzinga.com/news/contracts/24/12/42432652/marvell-debuts-game-changing-lpo-chipset-for-data-centers-details" target="_blank" rel="noopener">가용성을 발표</a>했다. 이는 AI 기반 데이터 센터가 인터커넥트 솔루션 최적화의 필요성을 높일 수 있기 때문이다.
여러 애널리스트들은 이 회사의 3분기 재무 결과 발표 후 <a href="https://www.benzinga.com/news/earnings/earnings-beats/24/12/42321281/marvell-technology-posts-solid-q3-beat-analysts-raise-forecasts-expect-40-50-earnings-growth" target="_blank" rel="noopener">주가 목표를 상향 조정</a>했다. 금요일 이 주식은 10.79% 급등한 120.77달러에 마감되었다. 주가는 2024년 연초 대비 107.62% 상승했다.
<img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13134140/Screenshot-272.png?optimize=medium&amp;dpr=1.25&amp;auto=webp&amp;width=2048" />
다음 주 보고서를 계속 지켜봐 주시기 바랍니다. <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent111524&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">여기에서</a> Benzinga Pro를 팔로우하여 모든 최신 헤드라인과 시장을 움직이는 주요 기사를 확인하세요.
여기에서 최근 ‘스톡 위스퍼 지수' 보고서를 읽어보세요.
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EB%B2%A4%EC%A7%95%EA%B0%80%EC%9D%98-%EC%8A%A4%ED%86%A1-%EC%9C%84%EC%8A%A4%ED%8D%BC-%EC%A7%80%EC%88%98-%ED%94%84%EB%A1%9C%ED%83%80%EB%9D%BC-%EB%A7%88%EB%9D%BC-%ED%8A%B8%EB%A0%88/" target="_blank" rel="noopener">12월 7일</a></li>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EB%B2%A4%EC%A7%95%EA%B0%80%EC%9D%98-%EC%8A%A4%ED%86%A1-%EC%9C%84%EC%8A%A4%ED%8D%BC-%EC%A7%80%EC%88%98-%EC%82%AC%EC%9D%B4%EB%A8%BC-%ED%94%84%EB%A1%9C%ED%8D%BC%ED%8B%B0-%EC%95%A8%EB%A6%AC/" target="_blank" rel="noreferrer noopener">11월 30일</a></li>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EB%B2%A4%EC%A7%95%EA%B0%80%EC%9D%98-%EC%8A%A4%ED%86%A1-%EC%9C%84%EC%8A%A4%ED%8D%BC-%EC%A7%80%EC%88%98-%EB%8D%B8%ED%83%80-%ED%95%AD%EA%B3%B5-%EB%82%98%EC%9D%B4%ED%82%A4-%EC%98%A4%ED%86%A0/" target="_blank" rel="noreferrer noopener">11월 23일</a></li>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EB%B2%A4%EC%A7%95%EA%B0%80%EC%9D%98-%EC%8A%A4%ED%86%A1-%EC%9C%84%EC%8A%A4%ED%8D%BC-%EC%A7%80%EC%88%98-%EC%95%A1%EC%86%90-%EC%8A%A4%EB%85%B8%EC%9A%B0%ED%94%8C%EB%A0%88%EC%9D%B4-%EC%97%A0/" target="_blank" rel="noreferrer noopener">11월 16일</a></li>
</ul>
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

벤징가의 '스톡 위스퍼' 지수: 스냅, 실스Q, 버티브, 다나허 및 마벨 테크놀로지

화요일에, 다나허(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>)는 3분기 매출이 57억 9천만 달러로 전년 대비 3% 증가했으며, <a href="https://www.benzinga.com/news/earnings/24/10/41449367/life-science-giant-danaher-q3-earnings-revenue-and-eps-beat-sticks-to-annual-guidance" target="_blank" rel="noreferrer noopener">컨센서스 55억 9천만 달러</a>를 상회했다고 보고했다.
가이던스: 다나허(Danaher)는 2024 회계연도 비GAAP 핵심 매출이 전년 대비 낮은 한 자릿수로 감소할 것임을 재확인했다.
이 회사는 2024년 바이오프로세싱 핵심 매출이 낮은 한 자릿수로 감소할 것으로 예상하고 있으며, 세파이드(Cepheid) 2024 호흡기 매출은 이전 지침 16억 달러에 비해 약 17억 달러가 될 것으로 예상한다.
윌리엄 블레어(William Blair)는 도나허의 3분기 실적이 특히 바이오프로세싱의 지속적인 회복과 관련하여 기대에 부합했다고 보고했다. 그러나 자본 지출은 여전히 약세이다.
이 애널리스트는 회복 테마가 예상대로 진행되고 있으며, 결과가 분기 중 산업 컨퍼런스 업데이트에서 본 유사한 트렌드를 반영하고 있다고 강조했다.
3분기 B2B는 약 1.0배로 개선되어 1년 전의 0.80배에서 상승했으며 순차 주문의 높은 한 자릿수 증가가 바이오프로세싱 반등을 더욱 뒷받침했다.
장비 부문에서 생명과학 장비는 예측 및 분기 내 관찰과 일치하여 한 자릿수 중반 감소를 보였다.
한편, 진단 부문은 잘 수행되었으며, 세파이드의 호흡기 매출은 다시 한 번 기대를 초과했다.
가이던스에 대해 경영진은 생명공학 분야의 4분기에 중간에서 높은 한 자릿수 핵심 성장률을 기대한다. 이 애널리스트는 컨퍼런스 콜의 초점이 바이오프로세싱의 4분기 종료율, 2025년 초기 통찰력, 자본 장비의 약세 및 중국에 대한 업데이트된 생각이 될 것으로 예상하고 있다.
윌리엄 블레어는 아웃퍼폼 등급을 유지하고 있다. 골드만삭스는 중립 등급을 유지하며, <a href="https://www.benzinga.com/quote/dhr/analyst-ratings">목표 주가를 250달러로 설정</a>했다.
주가 움직임: 다나허의 주식은 화요일 3.97% 하락한 261.28달러에 마감되었다.
사진 출처: Shutterstock
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

이들 11개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
<ol>
<li>QXO(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QXO#NASDAQ">QXO</a>)의 주가는 <a href="https://www.benzinga.com//node/39880836" target="_blank" rel="noreferrer noopener">사모 금융 유치</a>를 발표한 이후 33.37% 상승했다.</li>
<li>아반토(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVTR#NYSE">AVTR</a>)의 주식은 S&amp;P MidCap 400에 편입된다는 발표 이후 지난 주에 21.62% 상승했다. 또한 예상보다 나은 2분기 실적을 발표했다.</li>
<li>유니버셜 헬스 서비스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>)는 회사가 예상보다 나은 2분기 실적을 발표하고 <a href="https://www.benzinga.com//node/39942622" target="_blank" rel="noreferrer noopener">2024 회계연도 지침을</a> 상향 조정한 후 주가가 17.73% 상승했다.</li>
<li>맨하탄 어소시에이츠(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MANH#NASDAQ">MANH</a>)의 주가는 예상보다 나은 2분기 재무 결과를 보고한 후 17.02% 상승했다. 몇몇 분석가들은 주식에 대한 가격 <a href="https://www.benzinga.com/quote/MANH/analyst-ratings" target="_blank" rel="noreferrer noopener">예측</a>을 높였다.</li>
<li>몰리나 헬스케어(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>)의 주가는 <a href="https://www.benzinga.com//node/39942485" target="_blank" rel="noreferrer noopener">예상보다 좋은 2분기 실적</a>에 힘입어 15.53% 상승했다.</li>
<li>퍼스트 시티즌스 뱅크셰어스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCNCA#NASDAQ">FCNCA</a>)의 주가는 회사의 분기 실적이 예상보다 높았음을 보고한 후 15.15% 상승했다.</li>
<li>테넷 헬스케어(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>)는 예상보다 나은 2분기 재무 결과를 보고한 후 주가가 13.02% 상승했으며, 회사는 FY24 지침을 추정치보다 높이고 3분기 지침을 추정치보다 높게 발표했다. 또한 회사는 <a href="https://www.benzinga.com//node/39934114" target="_blank" rel="noreferrer noopener">15억 달러 규모의</a> 자사주 매입을 승인했다고 발표했다.</li>
<li>CBRE 그룹(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CBRE#NYSE">CBRE</a>)은 회사가 2024년 목표를 상향 조정한 후 지난 주 주가가 12.99% 상승했다. 몇몇 분석가들은 주식에 대한 가격 <a href="https://www.benzinga.com/quote/MANH/analyst-ratings" target="_blank" rel="noreferrer noopener">예측</a>을 높였다.</li>
<li>써모 피셔 사이언티픽(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>)의 주가는 지난주 12.63% 상승했다. 이 회사는 연간 전망을 <a href="https://www.benzinga.com//node/39930516" target="_blank" rel="noreferrer noopener">상향 조정</a>했다.</li>
<li>다나허(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>)의 주가는 회사가 예상보다 나은 2분기 실적을 보고한 후 11.30% 상승하여 더 높게 거래되고 있다.</li>
<li>록히드 마틴(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>)의 주가는 긍정적인 애널리스트 <a href="https://www.benzinga.com//node/39941283" target="_blank" rel="noreferrer noopener">평가와 강한 2분기 실적</a>에 힘입어 10.72% 상승했다.</li>
</ol>
다음 기사:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%ed%8f%ac%eb%93%9c-%ec%8a%a4%ed%85%94%eb%9e%80%ed%8b%b0%ec%8a%a4-%eb%b0%8f-%eb%8d%b8%ec%9d%80-%ec%a7%80%eb%82%9c%ec%a3%bc-%ec%b5%9c%ec%95%85%ec%9d%98-%ec%84%b1%ea%b3%bc%eb%a5%bc-%eb%b3%b4%ec%9d%b8-12/" target="_blank" rel="noopener">포드, 스텔란티스 및 델은 지난주 최악의 성과를 보인 12개 대형주 중 일부 (7월 21일~7월 27일)</a></li>
</ul>
썸네일 제공: 셔터스톡
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Danaher

뉴스

에 대한 최신 뉴스 Danaher (NYSE:DHR) 주식

토요일, 12월 14, 2024

화요일, 10월 22, 2024

일요일, 7월 28, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌